RPGLIFE — RPG Life Sciences Income Statement
0.000.00%
- IN₹29.68bn
- IN₹28.40bn
- IN₹5.82bn
- 91
- 13
- 87
- 73
Annual income statement for RPG Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,756 | 3,891 | 4,402 | 5,128 | 5,821 |
Cost of Revenue | |||||
Gross Profit | 2,294 | 2,402 | 2,773 | 3,283 | 3,735 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,380 | 3,357 | 3,695 | 4,248 | 4,710 |
Operating Profit | 376 | 535 | 707 | 880 | 1,111 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 365 | 536 | 732 | 917 | 1,178 |
Provision for Income Taxes | |||||
Net Income After Taxes | 290 | 400 | 515 | 676 | 877 |
Net Income Before Extraordinary Items | |||||
Net Income | 290 | 400 | 515 | 676 | 877 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 290 | 400 | 515 | 676 | 877 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 20.2 | 24.2 | 31.1 | 41.2 | 53 |
Dividends per Share |